ICGA for Vascular Embolism After Hyaluronic Acid Injection (NCT07581652) | Clinical Trial Compass
CompletedNot Applicable
ICGA for Vascular Embolism After Hyaluronic Acid Injection
China19 participantsStarted 2025-07-01
Plain-language summary
Facial vascular embolism following hyaluronic acid injection is a rare but potentially serious complication that may lead to tissue ischemia, necrosis, and scarring. Early assessment of local tissue perfusion is important for evaluating treatment response and predicting clinical outcomes.
This retrospective observational study aims to evaluate whether indocyanine green angiography (ICGA) can provide objective, real-time information on tissue perfusion in patients with facial vascular embolism after hyaluronic acid injection. The study will review existing medical records, ICGA imaging data, and follow-up information from patients treated at a single center. The main question is whether ICGA findings before and after initial rescue therapy can help assess early perfusion recovery and identify patients who may require additional intervention or develop persistent tissue damage.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* History of facial hyaluronic acid injection.
* Clinical diagnosis of facial vascular embolism after hyaluronic acid injection, with symptoms or signs such as pain, skin color change, livedo-like discoloration, delayed capillary refill, or tissue ischemia.
* Received initial rescue treatment at the study center.
* Had indocyanine green angiography imaging performed before and immediately after initial rescue treatment as part of routine clinical care.
* Had sufficient medical records and follow-up information available to assess subsequent treatment and tissue outcomes.
Exclusion Criteria:
* Incomplete indocyanine green angiography imaging data.
* Insufficient medical records or follow-up information to assess the main study outcomes.
* Missing key clinical information needed for study analysis.
* Duplicate records or records with concerns about data reliability.
* The patient or legal representative explicitly objected to the use of historical clinical data for this study, if applicable under local ethics requirements.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Median Within-Participant Change in ICGA-Derived Ingress Rate From Before to After Initial Rescue Therapy
Timeframe: Periprocedural: immediately before initial rescue therapy and immediately after completion of initial rescue therapy
2
Median Within-Participant Change in ICGA-Derived Time to Peak From Before to After Initial Rescue Therapy
Timeframe: Periprocedural: immediately before initial rescue therapy and immediately after completion of initial rescue therapy
3
Median Within-Participant Change in ICGA-Derived Curve Ingress From Before to After Initial Rescue Therapy
Timeframe: Periprocedural: immediately before initial rescue therapy and immediately after completion of initial rescue therapy